Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from helios

10.1002/phar.2410

http://scihub22266oqcxt.onion/10.1002/phar.2410
suck pdf from google scholar
32339304!7267490!32339304
unlimited free pdf from europmc32339304    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32339304  :  Publisher
PDF vom PMID32339304

suck abstract from ncbi

pmid32339304
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression #MMPMID32339304
  • Johnson KM; Belfer JJ; Peterson GR; Boelkins MR; Dumkow LE
  • Pharmacotherapy 2020[Jun]; 40 (6): 517-524 PMID32339304show ga
  • Novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome virus (SARS-CoV-2) has become a global health care crisis. The Centers for Disease Control and Prevention (CDC) lists immunocompromised patients, including those requiring immunosuppression following renal transplantation, as high risk for severe disease from SARS-CoV-2. Treatment for other viral infections in renal transplant recipients often includes a reduction in immunosuppression; however, no current guidelines are available recommending the optimal approach to managing immunosuppression in the patients who are infected with SARS-CoV-2. It is currently advised to avoid corticosteroids in the treatment of SARS-CoV-2 outside of critically ill patients. Recently published cases describing inpatient care of COVID-19 in renal transplant recipients differ widely in disease severity, time from transplantation, baseline immunosuppressive therapy, and the modifications made to immunosuppression during COVID-19 treatment. This review summarizes and compares inpatient immunosuppressant management strategies of recently published reports in the renal transplant population infected with SARS-CoV-2 and discusses the limitations of corticosteroids in managing immunosuppression in this patient population.
  • |*Immunocompromised Host[MESH]
  • |Adrenal Cortex Hormones/administration & dosage/*therapeutic use[MESH]
  • |Betacoronavirus[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*epidemiology[MESH]
  • |Humans[MESH]
  • |Immunosuppressive Agents/administration & dosage/*therapeutic use[MESH]
  • |Kidney[MESH]
  • |Kidney Transplantation/*methods[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*epidemiology[MESH]
  • |SARS-CoV-2[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    517 6.40 2020